Core Viewpoint - The company anticipates a significant decline in net profit for the fiscal year 2025, projecting a decrease of 63.26% to 72.13% compared to the previous year, primarily due to non-recurring gains and market pressures [2][4]. Group 1: Performance Forecast - The performance forecast applies to a scenario where the company achieves profitability but experiences a net profit decline of over 50% compared to the same period last year [2]. - For the fiscal year 2025, the company expects a net profit attributable to shareholders of the parent company to be between 110 million and 145 million yuan, representing a year-on-year decrease of 24.962 million to 28.462 million yuan [4]. - The forecasted net profit, excluding non-recurring gains and losses, is expected to be between 80 million and 118 million yuan, reflecting a year-on-year decrease of 9.058 million to 12.858 million yuan [4]. Group 2: Previous Year’s Performance and Financial Status - In the previous year, the total profit was 433.9014 million yuan, with a net profit attributable to shareholders of the parent company at 394.6157 million yuan [6]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was 208.5835 million yuan, with earnings per share at 0.44 yuan [6]. Group 3: Reasons for Performance Decline - The decline in performance is primarily attributed to the impact of non-recurring gains from the previous year, where significant asset disposal gains were realized due to the completion of land transfer procedures [6]. - Market factors such as reduced product demand, intense industry competition, and price reductions from national procurement policies have pressured overall industry profits, leading to a decline in revenue and gross profit for the company [6]. - Strategic investments in high-quality development and increased R&D expenditures for innovative drugs and high-end formulations have also contributed to short-term cost pressures affecting profits [6].

鲁抗医药表示，本期业绩预减的主要原因为非经常性损益的影响，市场因素影响，以及战略投入与短期 成本压力。上年同期公司南厂区土地办理完成移交手续，土地完成整体移交后产生大额的资产处置收 益，导致本期业绩较上年同期变动幅度较大。同时，受产品市场需求放缓、行业竞争激烈以及国家集采 降价等政策性因素影响，行业整体利润承压，传统人用制剂产品终端需求变化较大，面临量价调整的压 力，公司相关业务营收及毛利同比有所下降，影响短期盈利表现。此外，为推进公司高质量发展战略的 落地，实施研发"精品工程"，公司持续加大创新药、高端制剂、合成生物的研发投入，前期获批文号及 批件等技术类资产摊销费用增加，研发投入保持在较高水平，短期对利润形成一定影响。 北京商报讯（记者 丁宁）1月27日晚间，鲁抗医药（600789）发布2025年业绩预告显示，预计2025年实 现归属净利润1.1亿元至1.45亿元，与上年同期相比，同比减少63.26%至72.13%。 ...